Zydus gets regulatory nod to market Lipaglyn in Mexico
Zydus Cadila has received approval from the Mexican regulatory authority to market Lipaglyn (Saroglitazar Magnesium) used for the treatment of dyslipidemia in patients with diabetes. The company... Analyst / Investor Meet - Intimation
Pursuant to Regulation 30 of the SEBI [Listing Obligations and Disclosure Requirements] Regulations, 2015, we hereby inform that the Company has planned investor interaction through a teleconference call at 5.00 p.m. on Monday, November 13, 2017 for Q2 FY 18 post results Q&A; session. Notice For The Meeting Of Board Of Directors / Closure Of Trading Window
We hereby inform that a meeting of the Board of Directors of the Company will be held on Monday, November 13, 2017 to consider apart from other agenda items to approve the unaudited financial results for the quarter / half year ended on September 30, 2017. Further, as per code of conduct for prevention of Insider Trading adopted by the Company under SEBI [Prohibition of Insider Trading] Regulations, 2015, the Trading Window will remain closed... Notice For The Meeting Of Board Of Directors / Closure Of Trading Window
We inform that a meeting of the Board of Directors of the Company will be held on Monday, November 13, 2017 to consider apart from other agenda items to approve the unaudited financial results for the quarter / half year ended on September 30, 2017. Further, as per code of conduct for prevention of Insider Trading adopted by the Company under SEBI [Prohibition of Insider Trading] Regulations, 2015, the Trading Window will remain closed from... Certificate Under Regulation 40 (10) Of SEBI (LODR) Regulations, 2015
The certificate as required under Regulation 40[10] of the SEBI [Listing Obligations and Disclosure Requirements], Regulations, 2017 for the half year - April 1, 2017 to September 30, 2017, issued by Hitesh Buch & Associates, Practicing Company Secretaries. Compliance Under Regulation 40 (10) Of SEBI (LODR), 2015
The certificate as required under Regulation 40[10] of the SEBI [Listing Obligations and Disclosure Requirements], Regulations, 2017 for the half year - April 1, 2017 to September 30, 2017, issued by Hitesh Buch & Associates, Practicing Company Secretaries. Compliance Under Regulation 40 (10) Of SEBI (LODR), 2015
The certificate as required under Regulation 40[10] of the SEBI [Listing Obligations and Disclosure Requirements], Regulations, 2017 for the half year - April 1, 2017 to September 30, 2017, issued by Hitesh Buch & Associates, Practicing Company Secretaries. Certificate Under Regulation 7 (3) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 For The Half Year Ended On September 30, 2017.
Certificate under Regulation 7 (3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the Half Year ended on September 30, 2017. Status Of Complaints As On September 30, 2017
In compliance with the provisions of Regulation 13[3] of the SEBI [Listing Obligations and Disclosure Requirements] Regulations, 2015, the status of Investor Complaints as on September 30, 2017 is as under: Sr. No. Particulars Status of Complaints 1. Complaints pending at the beginning of the quarter Nil 2. Complaints received during the quarter 3 3. Complaints disposed of during the quarter 3 4. Complaints remaining unresolved at the end of the quarter Nil Shareholding for the Period Ended September 30, 2017
Zydus Wellness Ltd has submitted to BSE the Shareholding Pattern for the Period Ended September 30, 2017. For more details, kindly Click here